Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HE-2200
- Development stage
- Discontinued
- Lead developer
- Harbor Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
HE-2200 is a synthetic androgenic steroid also known as beta-AET or Reversionex. It acts primarily as an agonist of the androgen receptor and has been investigated for its immunomodulatory properties. The drug was developed for potential use in treating adverse effects of chemotherapy (such as neutropenia), hyperlipidemia (including hypercholesterolemia), autoimmune diseases (such as multiple sclerosis and inflammatory bowel disease), immunologic deficiency syndromes including HIV/AIDS-related conditions and viral hepatitis B. Its mechanism involves modulation of immune responses via androgen receptor activation[1][2][3][4][6]. Development reached up to phase 2 clinical trials before being discontinued.
- Brand names
- Reversionex
- Other names
- 3beta,7beta,17beta-androstenetriolAndrost-5-ene-3,7,17-triol (3beta,7beta,17beta)(3S,7R,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-dodecahydro-cyclopenta[a]phenanthrene-3,7,17-triolQ0CZ537GC8Q-0CZ537GC8Q 0CZ537GC82697-85-0
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on HE-2200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HE-2200.